文献速递神经儿科影像MR

超极化13C代谢成像在弥漫性内生性桥脑胶质瘤及其他中枢神经系统肿瘤患儿中的初步研究

Pilot Study of Hyperpolarized 13C Metabolic Imaging in Pediatric Patients with Diffuse Intrinsic Pontine Glioma and Other CNS Cancers.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-12-03

该初步安全性研究纳入10例3至18岁既往诊断为脑肿瘤的患儿,评估超极化[1-13C]丙酮酸代谢成像的安全性与耐受性,6例完成注射与动态超极化13C MR成像。完成者在0.34 mL/kg(n=3)与0.43 mL/kg(n=3)两个剂量水平均耐受良好,未见剂量限制性毒性或不良事件,脑内可见[1-13C]丙酮酸转化为[1-13C]乳酸与[13C]碳酸氢盐。因入组不佳,研究在最高剂量水平仅纳入3例后关闭。

要点

  • 超极化[1-13C]丙酮酸在完成研究的6例患儿中耐受良好,两个剂量水平均未见剂量限制性毒性或不良事件。
  • 脑内可见超极化[1-13C]丙酮酸向[1-13C]乳酸和[13C]碳酸氢盐的特征性转化。
  • 10例入组患儿中4例因超极化[1-13C]丙酮酸制备或MR成像操作相关技术故障未能完成超极化13C MR成像。

诊断标准与关键数值

  • 评估两个剂量水平:0.34 mL/kg(n=3)与最高耐受成人剂量0.43 mL/kg(n=3)。
  • 完成研究的全部患儿耐受良好,两个剂量水平均未见剂量限制性毒性或不良事件。
  • 脑内观察到超极化[1-13C]丙酮酸特征性转化为[1-13C]乳酸和[13C]碳酸氢盐。

局限性

  • 因入组不佳,研究在最高剂量水平仅纳入3例参与者后关闭。
  • 10例入组参与者中4例因超极化[1-13C]丙酮酸制备或MR成像操作相关技术故障未能接受超极化13C MR成像。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Pediatric CNS tumors commonly present challenges for radiographic interpretation on conventional MR imaging. This study sought to investigate the safety and tolerability of hyperpolarized carbon-13 (HP-13C) metabolic imaging in pediatric patients with brain tumors.

MATERIALS AND METHODS: Pediatric patients 3 to 18 years of age who were previously diagnosed with a brain tumor and could undergo MR imaging without sedation were eligible to enroll in this safety study of HP [1-13C]pyruvate. Participants received a one-time injection of HP [1-13C]pyruvate and were imaged using dynamic HP-13C MR imaging. We assessed 2 dose levels: 0.34 mL/kg and the highest tolerated adult dose of 0.43 mL/kg. Participants were monitored throughout imaging and for 60 minutes postinjection, including pre- and postinjection electrocardiograms and vital sign measurements.

RESULTS: Between February 2017 and July 2019, ten participants (9 males; median age, 14 years; range, 10-17 years) were enrolled, of whom 6 completed injection of HP [1-13C]pyruvate and dynamic HP-13C MR imaging. Four participants failed to undergo HP-13C MR imaging due to technical failures related to generating HP [1-13C]pyruvate or MR imaging operability. HP [1-13C]pyruvate was well-tolerated in all participants who completed the study, with no dose-limiting toxicities or adverse events observed at either 0.34 (n = 3) or 0.43 (n = 3) mL/kg. HP [1-13C]pyruvate demonstrated characteristic conversion to [1-13C]lactate and [13C]bicarbonate in the brain. Due to poor accrual, the study was closed after only 3 participants were enrolled at the highest dose level.

CONCLUSIONS: Dynamic HP-13C MR imaging was safely performed in 6 pediatric patients with CNS tumors and demonstrated HP [1-13C]pyruvate brain metabolism.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Autry AW, Park I, Kline C, et al. Pilot Study of Hyperpolarized 13C Metabolic Imaging in Pediatric Patients with Diffuse Intrinsic Pontine Glioma and Other CNS Cancers. AJNR Am J Neuroradiol. 2020. PMID: 33272950. doi:10.3174/ajnr.A6937

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。